ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,793.30
1.44%
S&P ASX All Technology
3,068.10
1.62%
Brent Oil
83.00
-0.57%
US Dollar vs AUD
1.51323
0.23%
Bitcoin
63,546.01
0.60%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) News

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALNY
DateTimeSourceHeadlineSymbolCompany
02/05/202422:00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202421:00PR Newswire (US)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202421:00PR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202422:00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202422:00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202423:00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202422:30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202422:50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202409:39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202423:30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202408:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
28/02/202400:30Business WireAlnylam to Webcast Presentations at Upcoming March Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/02/202408:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/02/202408:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/02/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
16/02/202408:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
16/02/202400:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
16/02/202400:00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
10/02/202410:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/02/202408:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/01/202400:00Business WireAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY

Your Recent History

ASX
WBC
Westpac Banking
FX
GBPAUD
Sterling vs AUD
FX
AUDUSD
AUD vs US Dollar
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
ASX
FMG
Fortescue
FX
AUDCAD
AUD vs CAD
ASX
WPL
Woodside Petroleum
ASX
NCM
Newcrest Mining
ASX
BHP
BHP
ASX
WES
Wesfarmers
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
COIN
ETHUSD
Ethereum
NYSE
VZ
Verizon Communications
ASX
ORG
Origin Energy
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved